Plasma thromboxane and prostacyclin are linearly related and increased in patients presenting with acute myocardial infarction

P. A. Gurbel, S. R. Murugesan, D. R. Lowry, V. L. Serebruany

Research output: Contribution to journalArticle

Abstract

The role of prostanoids in patients with ischemic heart disease including acute myocardial infarction (AMI) has been recognized. However, there is very limited knowledge of the baseline TXB2 and 6-keto-PGF(1a) plasma levels in patients with AMI before therapy has been administered. We compared plasma levels of TXB, and 6-keto-PGF(1a) by enzyme immunoassay in 18 AMI patients before thrombolysis, with those of 13 healthy controls. Plasma levels of TXB2 (319.78 ± 16.50 pg/ml) and 6-keto-PGF(1a) (536.72 ± 56.71 pg/ml) were heterogeneous, but significantly higher in the AMI patients than in controls (175.92 ± 17.29 pg/ml and 192.08 ± 26.11 pg/ml, respectively). In some patients, long-term aspirin therapy mildly inhibits baseline prostanoid levels, however, limited data prevents us from further speculations on this issue. Although, the contributions by prostanoids to the pathogenesis of AMI have been well proposed, their plasma concentrations are not uniformly elevated, and it is still unclear whether the resultant changes are indicative of clinically meaningful effects.

Original languageEnglish (US)
Pages (from-to)7-11
Number of pages5
JournalProstaglandins Leukotrienes and Essential Fatty Acids
Volume61
Issue number1
DOIs
StatePublished - Jul 1999

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology

Fingerprint Dive into the research topics of 'Plasma thromboxane and prostacyclin are linearly related and increased in patients presenting with acute myocardial infarction'. Together they form a unique fingerprint.

  • Cite this